Chemistry:Zasocitinib
From HandWiki
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriasis, psoriatic arthritis and Crohn's disease.[1][2][3] It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile.[4]
See also
References
- ↑ "Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279". Journal of Medicinal Chemistry 66 (15): 10473–10496. August 2023. doi:10.1021/acs.jmedchem.3c00600. PMID 37427891.
- ↑ "The investigational tyrosine kinase inhibitor TAK-279 is effective and well tolerated in patients with active psoriatic arthritis in phase 2b study.". Cleveland Clinic Journal of Medicine. 14 November 2023. https://www.ccjm.org/page/acr-2023/tyrosine-kinase.
- ↑ "Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis.". American College of Rheumatology. 24 October 2023. https://acrabstracts.org/abstract/efficacy-and-safety-outcomes-of-tak-279-a-selective-oral-tyrosine-kinase-2-tyk2-inhibitor-from-a-randomized-double-blind-placebo-controlled-phase-2b-trial-in-patients-with-active-psoriatic-arthr/.
- ↑ "The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda.". synapse.patsnap.com. 10 August 2023. https://synapse.patsnap.com/blog/the-discovery-process-of-tak-279-and-the-deep-logic-behind-its-acquisition-by-takeda.
 |  |
